# The Re-Prosper HF Study

Study · id `cardio:ct-nct04551222` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04551222](<https://clinicaltrials.gov/study/NCT04551222>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04551222

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 125 participants.

## Technical summary

Registry record NCT04551222. Randomized; quadruple masking; primary purpose treatment. Start 2021-06-09 (actual); primary completion 2025-12-31 (actual). Results posted on 2026-09-14.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 125 participants (enrolled count; ClinicalTrials.gov record NCT04551222, source copy `cardio:ctgov-nct04551222-2026-09-14`, retrieved 2026-10-26)
- Started: 2021-06-09 (actual) (ClinicalTrials.gov record NCT04551222, source copy `cardio:ctgov-nct04551222-2026-09-14`, retrieved 2026-10-26)
- Primary completion: 2025-12-31 (actual) (ClinicalTrials.gov record NCT04551222, source copy `cardio:ctgov-nct04551222-2026-09-14`, retrieved 2026-10-26)
- Completion: 2025-12-31 (actual) (ClinicalTrials.gov record NCT04551222, source copy `cardio:ctgov-nct04551222-2026-09-14`, retrieved 2026-10-26)
- Results first posted: 2026-09-14 (ClinicalTrials.gov record NCT04551222, source copy `cardio:ctgov-nct04551222-2026-09-14`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT04551222, source copy `cardio:ctgov-nct04551222-2026-09-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04551222-2026-09-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Re-Prosper HF Study
- Acronym: Re-Prosper HF
- Condition: Heart Failure
- Intervention (Drug): probenecid
- Intervention (Drug): Placebo
- Lead sponsor: VA Office of Research and Development
- Lead sponsor class: FED

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: VA Office of Research and Development (`cardio:org-va-office-of-research-and-development`)

## Provenance

Content hash: 7ee9b017bf6eada4ba655d1afa829377a15884149fe03a4ee217edbaffdc337b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
